Biocon wins EMA CHMP positive opinion for Pertuzumab biosimilar Pebrilzo
EMA’s CHMP issued a positive opinion recommending EU marketing authorization for Biocon’s Pertuzumab biosimilar Pebrilzo for HER2-positive breast cancer; final European Commission decision is pending.
EMA’s CHMP has issued a positive opinion recommending EU marketing authorization for Biocon’s Pertuzumab biosimilar Pebrilzo for HER2-positive breast cancer. A final European Commission decision is still pending.